Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.61 |
| ▸ | GSK3B | P49841 | 13/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205280 | 0.82 | GSK3B (0.80) | PTPN1GSK3BNPC1RAB9AHDAC6 | |
| SCHEMBL1194372 | 0.77 | GSK3B (0.52) | PTPN1GSK3BAKR1C3AKR1C2 | |
| SCHEMBL10327311 | 0.76 | PTPN1 (1.00) | PTPN1GSK3BNPC1RAB9A | |
| SCHEMBL120278 | 0.76 | PTPN1 (1.00) | PTPN1GSK3BNPC1RAB9A | |
| SCHEMBL689331 | 0.75 | GSK3B (0.83) | PTPN1GSK3BRAB9A | |
| SCHEMBL28594745 | 0.75 | GSK3B (0.70) | PTPN1GSK3B | |
| SCHEMBL1194011 | 0.73 | GSK3B (0.46) | PTPN1GSK3B | |
| SCHEMBL1194001 | 0.73 | TSHR (0.60) | AKR1C3AKR1C2 | |
| SCHEMBL16161046 | 0.73 | AKR1C3 (0.41) | AKR1C3AKR1C2HDAC6 | |
| SCHEMBL70930 | 0.73 | GSK3B (1.00) | PTPN1GSK3BHDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079878-B2 | (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators | PFIZER LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | PFIZER LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296313-A1 | (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators | SCN8A, SCN1A, SCN5A | PTPN1 2244/4885GSK3B 2718/4885AKR1C3 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.